Poorly differentiated thyroid gland carcinoma

Summary

Poorly differentiated thyroid gland carcinoma (MONDO:0006382) is a cancer and 19 clinical trials. Top therapeutic interventions include cabozantinib, lenvatinib, and sorafenib. A subtype of adenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 19

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	poorly differentiated thyroid gland carcinoma
Mondo ID	MONDO:0006382
EFO	EFO:1000489
DOID	DOID:3972
ICD-11	1227619262
NCIT	C6040
UMLS	C1266050
MedGen	266094
Is cancer (heuristic)	yes

Also known as: insular carcinoma · poorly differentiated carcinoma of the thyroid gland · poorly differentiated carcinoma of thyroid gland · poorly differentiated thyroid cancer · poorly differentiated thyroid carcinoma · poorly differentiated thyroid gland cancer · poorly differentiated thyroid gland carcinoma · thyroid gland poorly differentiated carcinoma

Data availability: 9 cell lines.

Disease family

This is a subtype of adenocarcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › poorly differentiated thyroid gland carcinoma

Related subtypes (63): epididymal adenocarcinoma, rete testis adenocarcinoma, seminal vesicle adenocarcinoma, ethmoid sinus adenocarcinoma, lacrimal gland adenocarcinoma, papillary adenocarcinoma, fallopian tube adenocarcinoma, bladder adenocarcinoma, ovarian adenocarcinoma, trabecular adenocarcinoma, middle ear adenocarcinoma, bile duct adenocarcinoma, granular cell carcinoma, small intestine adenocarcinoma, urethra adenocarcinoma, villous adenocarcinoma, thymus gland adenocarcinoma, nasal cavity adenocarcinoma, ureter adenocarcinoma, adenocarcinoma in situ, gastroesophageal junction adenocarcinoma, maxillary sinus adenocarcinoma, mucinous adenocarcinoma, acinar cell carcinoma, adenoid cystic carcinoma, breast adenocarcinoma, clear cell adenocarcinoma, colorectal adenocarcinoma, endometrioid adenocarcinoma, esophageal adenocarcinoma, gastric adenocarcinoma, lung adenocarcinoma, prostate adenocarcinoma, renal cell carcinoma, signet ring cell carcinoma, cervical adenocarcinoma, serous adenocarcinoma, endometrium adenocarcinoma, sweat gland carcinoma, cystadenocarcinoma, tubular adenocarcinoma, mesonephric adenocarcinoma, scirrhous adenocarcinoma, pancreatic adenocarcinoma, follicular variant thyroid gland papillary carcinoma, gallbladder adenocarcinoma, hepatoid adenocarcinoma, intestinal type adenocarcinoma, micropapillary serous carcinoma, minor salivary gland adenocarcinoma, salivary gland basal cell adenocarcinoma, submandibular gland adenocarcinoma, sebaceous adenocarcinoma, hepatocellular carcinoma, parathyroid gland carcinoma, pituitary adenocarcinoma, vaginal adenocarcinoma, Paget disease, diffuse type adenocarcinoma, vulvar adenocarcinoma, thyroid gland adenocarcinoma, gastroesophageal adenocarcinoma, adenoacanthoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 19.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	16
EARLY_PHASE1	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02152995	PHASE2	ACTIVE_NOT_RECRUITING	Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
NCT03181100	PHASE2	ACTIVE_NOT_RECRUITING	Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer
NCT03449108	PHASE2	ACTIVE_NOT_RECRUITING	LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
NCT03914300	PHASE2	ACTIVE_NOT_RECRUITING	Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
NCT04171622	PHASE2	ACTIVE_NOT_RECRUITING	Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer
NCT04544111	PHASE2	ACTIVE_NOT_RECRUITING	PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
NCT04759911	PHASE2	ACTIVE_NOT_RECRUITING	Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
NCT06959641	PHASE2	RECRUITING	XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
NCT00654238	PHASE2	COMPLETED	Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer
NCT01811212	PHASE2	COMPLETED	Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
NCT02041260	PHASE2	UNKNOWN	A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting
NCT02393690	PHASE2	COMPLETED	Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer
NCT02973997	PHASE2	COMPLETED	Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)
NCT03387943	PHASE2	UNKNOWN	PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma
NCT03630120	PHASE2	TERMINATED	Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
NCT04731740	PHASE2	WITHDRAWN	Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer
NCT07485569	PHASE1	NOT_YET_RECRUITING	Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial
NCT06639191	EARLY_PHASE1	RECRUITING	[177Lu]Lu-AKIR001 First-in-human Study
NCT07068542	Not specified	RECRUITING	Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CABOZANTINIB	4	8
LENVATINIB	4	2
SORAFENIB	4	2
COBIMETINIB	4	1
DABRAFENIB	4	1
LIFILEUCEL	4	1
SELPERCATINIB	4	1
SELUMETINIB	4	1
TRAMETINIB	4	1
VANDETANIB	4	1
VEMURAFENIB	4	1
IODINE	3	2
SACITUZUMAB TIRUMOTECAN	3	1
SPARTALIZUMAB	3	1
ZANZALINTINIB	3	1
CHEMBL4215501	0	2
CHEMBL4849721	0	2
CHEMBL5433950	0	2
EXELIXIS	0	2
CHEMBL4463209	0	1
CHEMBL3415553	0	1
CHEMBL4209555	0	1
CHEMBL4538425	0	1
CHEMBL5430810	0	1
PLX-4720	0	1